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Abstract Sensory neuronopathies (SNNs) encompass paraneoplastic, infectious,
dysimmune, toxic, inherited, and idiopathic disorders. Recently described diagnostic criteria
allow SNN to be differentiated from other forms of sensory neuropathy, but there is no
validated strategy based on routine clinical investigations for the etiological diagnosis of
SNN. In a multicenter study, the clinical, biological, and electrophysiological characteristics
of 148 patients with SNN were analyzed. Multiple correspondence analysis and logistic
regression were used to identify patterns differentiating between forms of SNNs with
different etiologies. Models were constructed using a study population of 88 patients and
checked using a test population of 60 cases. Four patterns were identified. Pattern A, with
an acute or subacute onset in the four limbs or arms, early pain, and frequently affecting
males over 60 years of age, identified mainly paraneoplastic, toxic, and infectious SNN.
Pattern B identified patients with progressive SNN and was divided into patterns C and D,
the former corresponding to patients with inherited or slowly progressive idiopathic SNN
with severe ataxia and electrophysiological abnormalities and the latter to patients with
idiopathic, dysimmune, and sometimes paraneoplastic SNN with a more rapid course than
in pattern C. The diagnostic strategy based on these patterns correctly identified 84/88 and
58/60 patients in the study and test populations, respectively.
Key words: diagnostic strategy, paraneoplastic neurological syndrome, sensory
ganglionopathy, sensory neuronopathy, sensory neuropathy
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Introduction
Sensory neuronopathies (SNNs) are characterized
by primary involvement of sensory neurons in the
dorsal root ganglia (Kuntzer et al., 2004; Sghirlanzoni
et al., 2005), although, with particular etiologies, the
pathological process may extend to roots and nerves.
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SNNs encompass paraneoplastic disorders (Graus
et al., 1990; Dalmau et al., 1991; Wanschitz et al.,
1997; Antoine and Camdessanche´, 2007), infectious
disorders (Scaravilli et al., 1992; Esiri et al., 1993),
dysimmune disorders (Griffin et al., 1990; Mori et al.,
2005), and toxic, inherited, and idiopathic disorders
(Okajima et al., 1983; Sobue et al., 1988; Hainfellner
et al., 1996; Kurokawa et al., 1998; Colli et al., 2008).
The elaboration of an etiological diagnostic strategy
for these neuropathies, which is essential in terms of
therapeutic possibilities and prognosis for the patient,
involves two steps. The first is the differentiation
of SNN from other sensory neuropathies. We have
recently shown that a relatively simple set of criteria
established on a population of patients with disorders
known to depend on sensory neuron involvement
allows SNN to be differentiated from other sensory
neuropathies with good sensitivity and specificity
(Camdessanche´ et al., 2009) (Table 1), but do not
differentiate between different types of SNN with
different etiologies. The second step therefore is to
rapidly and accurately make a good final diagnosis of
the underlying cause of the neuropathy, but this is
frequently difficult, as it may only become apparent
months or years after onset and the initial negative
checkup. The aim of this study was to devise and
validate a suitable strategy for the diagnosis of the
underlying causes of SNN.
Materials and Methods
Patient selection
The study was approved by the Ethics Committee
of the University Hospital of Saint-Etienne, France.
Two populations of patients were included in the
study. The first, the ‘‘study’’ population, consisted
of 88 consecutive patients with a final diagnosis of
SNN referred to the Rhoˆne-Alpes Reference Centre
for Rare Neuromuscular Diseases before January 2009
(monocenter study). The second, the ‘‘test’’ popula-
tion, consisted of 60 patients with a final diagnosis of
SNN consecutively investigated in 15 Francophone ref-
erence centers for neuromuscular diseases, who were
entered in a French database of patients with SNN
after January 2009 (multicenter study). The monocen-
ter study population was used in the elaboration of the
diagnosis strategy, which was then checked against
the multicenter test population.
To be recruited in the study, all patients had (1) to
fulfill the diagnosis criteria of possible or probable
SNN (see Table 1 for detailed criteria) (Camdessanche´
et al., 2009), (2) to have been investigated until a final
etiological diagnosis of the SNN was made by the
methods routinely used in this center, which were
not based on the strategy proposed here, and (3) to
have been followed up for a sufficient period for any
underlying cause to become apparent before the final
diagnosis of idiopathic SNN was made.
For each patient, a complete and detailed record of
the clinical and electrophysiological investigations had
to be available; these included laboratory investigations
including screening for diabetes mellitus, renal failure,
abnormal white blood cell count, plasma ion abnor-
malities, monoclonal gammopathy, liver perturbations,
B12 deficiency, thyroid hormone abnormalities, and
well-characterized onconeural antibodies and organ-
or non-organ-specific antibodies, including antinuclear,
mitochondrial, SSA, and SSB antibodies, and serology
for human deficiency virus (HIV) and hepatitis B and
C. In addition, a chest and abdominal computerized
tomography (CT) scan were performed in some cases
to search for a tumor. The patients were then clas-
sified into six etiological categories: (1) paraneoplastic
SNN, defined by the presence of onconeural antibod-
ies or a cancer within 2 years before or after onset,
(2) toxic neuropathies, including patients treated with
platin salts or with chronic B6 consumption or high
Table 1. The diagnostic criteria for SNN used in the study.
Step A: In a patient with a clinically pure sensory neuropathy, a diagnosis of SNN is considered possible if the
total score is >6.5
Points
Ataxia in the lower or upper limbs at onset or full development +3.1
Asymmetrical distribution of sensory loss at onset or full development +1.7
Sensory loss not restricted to the lower limbs at full development +2.0
At least one SAP absent or three SAPs <30% of the lower limit of normal in the upper limbs, not explained by
entrapment neuropathy
+2.8
Fewer than two nerves with abnormal motor NCS results in the lower limbs +3.1
Step B: A diagnosis of SNN is probable if the patient’s score is >6.5 and if the initial workup does not show biological
perturbations or ENMG findings excluding SNN and the patient has one of the following disorders: onconeural AB or a
cancer 5 years before or after onset, cisplatin treatment, or Sjo¨gren’s syndrome or if the MRI shows a high signal in the
posterior column of the spinal cord
Step C: A diagnosis of SNN is definite if DRG degeneration is pathologically demonstrated, although DRG biopsy is
not recommended
AB, antibody; DRG, dorsal root ganglia; ENMG, electroneuromyogram; MRI, magnetic resonance imaging; NCS, nerve conduction study;
SAP, sensory action potential; SNN, sensory neuronopathy.
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alcohol consumption, (3) neuropathies associated with
a dysimmune context, (4) infectious SNN, (5) inherited
neuropathies with either an identified mutation or
a well-established family history, and (6) idiopathic
neuropathies.
Clinical data recorded for the study
Clinical characteristics
The following data were recorded: (1) sex and age,
(2) family history, (3) at disease onset, the modality
of onset (acute ≤1 month, subacute >1 month and
≤6 months, or progressive >6 months), presence of
paresthesia/dysesthesia, ataxia, or pain and initial
involvement of only the lower or upper limbs or
all four limbs, and (4) at maximum development of
the neuropathy, a topography of sensory loss in
the four limbs (proximal or distal), face, or trunk
and the presence of pain, dysesthesia/paresthesia,
ataxia in the upper or lower limbs, and small (thermal
and pin-prink sensation) or large (vibration and joint
position sense) fiber involvement, the number of
elicited tendon reflexes, symmetry or asymmetry of
the sensory loss, the modified Rankin score, and
autonomic system abnormalities, including orthostatic
hypotension, constipation, diarrhea, sexual impotence,
bladder disturbances, abnormal sweating, and pupil
abnormalities. Cerebrospinal fluid (CSF) abnormalities
included a protein concentration >0.5 g/l, a white cell
count >5/mm3, or an oligoclonal pattern.
Electroneuromyography
For the electrophysiological study at full develop-
ment of the neuropathy, conduction velocities were
recorded using a classical procedure in the median,
ulnar, and radial nerves in the forearm and peroneal,
tibial, superficial peroneal, and sural nerves in the leg.
Sensory action potentials (SAPs) were recorded in
the median, ulnar, radial, superficial, peroneal, and
sural nerves and expressed as a percentage of the
lower limit of the laboratory normal values. Motor
distal latencies, compound muscle action potential
(CMAP), and minimal F-wave latencies were recorded
for the median, ulnar, tibial, and peroneal nerves. The
electrophysiological pattern of each motor nerve was
classified as normal, axonal/neuronal, demyelinating,
or intermediate according to the published criteria
(Camdessanche´ et al., 2002).
Statistical analysis
Statistical analyses were performed using SPSS
14® software (IBM Corporation, Armonk, NY, USA).
The strategy used is summarized in Fig. 1. The study
population was used to generate a model of patterns
of SNN related to specific etiologies.
Figure 1. Flow chart for the strategy used in the study.
In the first step, multiple correspondence analysis
(MCA) was used as a descriptive method to identify
groups of patients in the study population who shared
a similar pattern (Benze´cri, 1973; Klecka, 1980; Be´cue-
Bertaut and Page`s, 2006). MCA is a multivariate
method for the exploratory study of multidimensional
contingency tables. It is powered to highlight similarity
and dissimilarity among a complex population by
providing a synthetic analysis of categories from a
battery of qualitative data. The distances between
variables in a multidimensional table containing all
the variable values are calculated to identify a small
number (usually 2) of dimensions or axes of inertia,
in which deviations from a reference value can be
graphically represented as an indication of relationship
between variables. The following variables were
entered into the analysis: age; sex; modality of onset
(acute–subacute vs. progressive); at onset, sensory
manifestations involving the upper limbs with an
asymmetrical distribution; and at full development,
sensory manifestations restricted to the lower limbs,
pain, ataxia, at least one abolished SAP in the upper
limbs, and presence of motor conduction velocity
abnormalities (more than one nerve with an abnormal
CMAP or conduction velocities) (Camdessanche´ et al.,
2009). Etiological category was introduced as a
supplementary variable, but not entered in the
calculation.
In the second step, univariate and multivariate
logistic regression analyses were used to identify the
clinical and electrophysiological items characterizing
the different types of SNN patterns based on the
etiology recognized by the MCA and to obtain a model
of these patterns. Receiver operating characteristic
(ROC) curves were used to measure the sensitivity
and specificity of the patterns. This allowed the
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construction of a flowchart providing a strategy for
the etiological diagnosis of SNN. In the third step, the
sensitivity and specificity of the proposed strategy was
checked using a prospective test population.
Results
Patients
The study and test populations consisted of 88
and 60 patients, respectively. Their characteristics
and etiological diagnosis are summarized in Table 2.
The two populations differed in terms of etiologies
and consequently sex, because the center that
recruited the study population is a reference center
for paraneoplastic disorders, in which there is a higher
frequency of males. Of the 148 patients, 66 fulfilled
the criteria for probable SNN and 82 for possible
SNN, none of the latter had electrophysiological
perturbations excluding SNN. In terms of the final
etiological diagnosis, 41 patients had paraneoplastic
SNN (3 without onconeural antibodies), 17 toxic SNN
(4 with high alcohol consumption and weight loss),
and 30 dysimmune SNN (12 Sjo¨gren’s syndrome,
6 monoclonal gammopathy – including 1 with
antidisialosyl ganglioside antibodies-, 1 lupus, 2 lupus
anticoagulant, 1 primary biliary cirrhosis, 1 kidney
graft,1 ulcerative colitis, 1 non-systemic vasculitis, and
5 unclassified dysimmune disorder). In two patients,
the SNN was linked to mycoplasma pneumonia or
HIV infection. Inherited SNN was seen in eight
patients: one with Friedreich ataxia and one with
mitochondriopathy with multiple mitochondrial DNA
deletions were definite inherited SNN, while one with
familial sensory neuropathy without an identified gene
and five with a family history including a pair of twins
corresponded to probable inherited SNN. One patient
had B12 deficiency and 49 had idiopathic SNN.
In the study population, a final etiological diagnosis
was made within 6 months after the first referral in 56
patients (28 paraneoplastic, 13 toxic, 10 dysimmune,
2 infectious, and 3 inherited) and between 6 months
and 10 years in 10 (mean 2.3 years, median 2.8 years;
5 dysimmune and 5 paraneoplastic), the longest delay
being observed in 2 patients with Sjo¨gren’s syndrome
(7 and 10 years, respectively). In the case of the
remaining 22 patients, no etiological diagnosis was
made after a mean follow-up of 10.1 years (median
9.5, range 1–21) after onset of symptoms, and the
SNN was considered idiopathic in these patients.
The time from referral to diagnosis was not
recorded in the test population, but the mean follow-
up was 6.2 years (median 2.8, range 0.5–45) after
neuropathy onset in patients with a final etiological
Table 2. Demographic characteristics and etiologies of
the sensory neuronopathies of the two populations used
in the study.
Study
population
Test
population
Number 88 60
Males/females 50/38 25/35
Age (mean + SD) 57.8 + 14.2 54.7 + 14.4
Paraneoplastic 33 8
With onconeural AB 31 7
Toxic 13 4
Platin salts 11 2
Alcohol 2 2
Dysimmune 13 17
Sjo¨gren’s syndrome 5 7
Lupus/lupus anticoagulant 2 1
Monoclonal gammopathy 2 4
Others 4 5
Infectious 2 0
Genetic/familial 3 5
Identified gene 0 2
Family history 3 3
Idiopathic 24 25
Others 0 1
AB, antibody; SD, standard deviation.
diagnosis and 4.6 years (median 2.7, range 1–20) in
idiopathic cases.
Patterns of SNN in the study population
Multiple correspondence analysis
The MCA was almost reliable, with a Chronbach’s
alpha value of 0.79 (reliable if ≥0.80). Two
dimensions were identified containing 32.9% of
the total variance. Dimension 1 was sensitive to
age, clinical manifestations at full development, and
electrophysiological abnormalities, whereas dimension
2 was sensitive to clinical manifestations at onset
and the course of the disease. As shown in Fig. 2A,
among the 88 patients, MCA identified two groups
which almost did not overlap, group A, consisting
of 41 patients with mainly paraneoplastic SNN (30
cases) or toxic SNN (10 cases), the remaining patients
having dysimmune SNN, and group B, consisting of 40
patients with dysimmune SNN (10 cases), idiopathic
SNN (23 cases), inherited SNN (3 cases), anti-Hu-
associated paraneoplastic SNN (1 case), infectious
SNN (1 case), or toxic SNN (2 cases). The remaining
seven patients (two paraneoplastic, two dysimmune,
one infectious, one toxic, and one idiopathic SNN) had
a pattern intermediate between these two groups.
As shown in Fig. 2B, group B could be subdivided
into two subgroups. Sixteen patients with genetic or
idiopathic SNN formed a cluster (group C) which did not
overlap with a group of 24 patients, which was a mix of
idiopathic or dysimmune SNN (dysimmune/idiopathic
SNN, group D).
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A B
Figure 2. Multiple correspondence analysis. (A) Distribution of the 88 patients in the study population in two-dimensional
space and identification of patients conforming to pattern A or pattern B. (B) In the patients conforming to pattern B,
identification of patients conforming to pattern C; pattern D corresponds to those patients with pattern B who do not conform
to pattern C. DYS, dysimmune; GEN, genetic; ID, idiopathic; PARA, paraneoplastic; TOX: toxic.
Logistic regression analysis
Logistic regression analysis was then used to
determine the clinical and electrophysiological char-
acteristics that distinguished pattern A from pattern
B and pattern C from pattern D (Tables 3 and 4). The
analysis was performed on 81 patients after exclusion
of the 7 patients with a pattern intermediate between
A and B.
Patterns A and B. Patients with pattern A (mostly
paraneoplastic and toxic SNN) were more frequently
males and were older than patients with pattern B
(mainly dysimmune and idiopathic SNN). In group A,
comparatively to group B, onset was frequently acute
or subacute with involvement of all four limbs or only
the arms and with pain as an early manifestation,
while at full development, pain and dysesthesia were
predominant, and in patients with paraneoplastic
disorders, the CSF results and motor conduction
velocities were frequently abnormal. Multivariate
analysis identified an older age (odds ratio [OR] 1.13:
1.0–1.27 95% confidence interval [CI], p < 0.05), male
sex (OR 44.4: 10.02–197.4 95% CI, p < 0.01), acute
or subacute onset (OR 189.9: 18.8–1896.4 95% CI,
p = 0.001), and painful onset (OR 7.9: 2.4–25.7 95%
CI, p < 0.05) less frequently restricted to the lower
limbs (OR 0.07: 0.002–0.19 95% CI, p < 0.01) as
factors characteristic of pattern A that distinguished
it from pattern B. The CSF was not included in the
analysis, as not all of the patients underwent a spinal
tap. Using ROC curves (Fig. 3A), the presence of at
least two of these items distinguished pattern A from
pattern B with 90% sensitivity and 75% specificity.
When these criteria established on the 81 patients
with either pattern A or B were applied to the whole
study population of 88 patients (Fig. 4), 100% of cases
of toxic SNN (13/13) and of infectious SNN (2/2), 85%
of cases of paraneoplastic SNN (28/33), and 0% of
cases of inherited SNN (0/3) were correctly identified.
The overall positive predictive value of these criteria
for these etiologies was 90%. However, only 59% of
patients with idiopathic SNN (14/24) and 29% of those
with dysimmune SNN (4/13) were identified, with an
overall positive predictive value of 38%, indicating
clinical heterogeneity in these two forms of SNN, for
which the criteria characterizing patterns C or D need
to be applied to accurately identify the etiology.
Patterns C and D. Compared to patients in the
overlapping group of idiopathic and dysimmune SNN
(pattern D), patients with pattern C (idiopathic or inher-
ited SNN) tended to be older. In group C, compared
to D, onset was more frequently progressive, with
ataxia as a predominating manifestation, and onset in
the lower limbs and absence of pain were marginally
significant. Extension of sensory loss to the trunk
was more frequent. Electrophysiologically, SAPs in
the four limbs were more severely abnormal. Multi-
variate analysis confirmed that this variety of SNN was
characterized by older age (OR 1.1: 1.01–1.20 95%
CI, p < 0.05), a slowly progressive course (OR 39.8:
2.84–558.9 CI, p < 0.01), and an electrophysiologically
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Table 3. Univariate logistic regression analysis showing the differential characteristics of the sensory neuronopathy
patterns identified by the multiple correspondence analysis.
Pattern A vs. B p-Value Pattern C vs. D p-Value
Age 1.03 (0.99–1.06) 0.07 1.04 (0.99–1.09) 0.07
Sex (males) 5.93 (2.23–15.76) 0.0004 2.57 (0.72–9.17) 0.14
Onset 40/41 22/26 16/27 —
Progressive 0.043 (0.01–0.16) 0.043 5.42 (1.25–23.49) 0.024
Dysesthesia 3.08 (0.88–10.82) 0.079 0.38 (0.09–1.54) 0.17
Ataxia 0.64 (0.27–1.54) 0.32 8.67 (1.96–38.41) 0.0045
Pain 2.93 (1.18–7.27) 0.020 0.29 (0.07–1.25) 0.097
Four limbs 5.48 (1.78–16.82) 0.003 NA 0.98
LL only 0.10 (0.03–0.32) <0.0001 3.20 (0.87–11.82) 0.08
UL only 1.83 (0.73–4.56) 0.20 0.91 (0.24–3.42) 0.89
Four limbs + LL only 0.61 (0.25–1.52) 0.29 1.29 (0.35–4.82) 0.70
Four limbs + UL only 10.80 (3.49–33.41) <0.0001 0.36 (0.10–1.34) 0.13
Full development
LL only 0.22 (0.02–2.11) 0.19 1.79 (0.23–14.1) 0.58
UL only 2.0 (0.17–22.9) 0.56 NA 0.98
Four limbs 1.81 (0.40–8.14) 0.44 0.35 (0.05–2.34) 0.27
Face 0.32 (0.08–1.29) 0.11 2.67 (0.51–13.9) 0.24
Trunk 0.51 (0.14–1.90) 0.51 11.82 (1.24–113.26) 0.032
Pain 4.04 (1.60–10.23) 0.0032 0.18 (0.03–0.94) 0.18
Dysesthesia 4.80 (1.24–18.82) 0.024 0.29 (0.07–1.17) 0.08
Dysautonomia 0.82 (0.27–2.53) 0.73 1.92 (0.41–9.05) 0.41
Small fiber involvement 0.85 (0.35–2.07) 0.71 0.54 (0.15–1.96) 0.35
Large fiber involvement 1.58 (50.25–10.01) 0.63 NA 0.97
Ataxia 0.79 (0.29–2.18) 0.79 NA 0.97
Rankin 1.43 (0.95–2.16) 0.085 1.03 (0.60–1.68) 0.99
CSF
Number 22/26 — 8/18 —
Abnormal∗ 13.7 (1.54–125.0) 0.07 1.5 (0.25–8.98) 0.66
Nerve conduction study
>1 SAP = 0 in UL 1.04 (0.42–2.59) 0.94 18.7 (2.16–162.9) 0.008
>2 SAP = 0 in UL 0.41 (0.16–1.02) 0.055 3.67 (0.99–13.6) 0.052
>1 SAP = 0 in LL 0.93 (0.36–2.37) 0.88 6.5 (1.22–34.7) 0.028
>2 SAP = 0 in LL 0.41 (0.16–1.02) 0.051 10.40 (1.92–56.11) 0.0065
Minor motor abnormalities 0.17 (0.06–0.49) 0.001 0.37 (0.07–1.95) 0.37
The values shown are the odds ratio and 95% confidence interval. Significant values are shown in bold. CSF, cerebrospinal fluid; LL, lower
limb; NA, not available; SAP, sensory action potential; UL, upper limb.
∗CSF abnormalities were a protein concentration >0.5 g/l, a white cell count >5/mm3, or an oligoclonal pattern.
Table 4. Summary of the main characteristics of the 4 patterns of SNNs. Patterns C and D are the two variants of
pattern B.
Pattern A Pattern B Pattern C Pattern D
Clinical features Acute/subacute, onset
in all four limbs or
only the arms, early
pain, frequently
males, and over
60 years
Progressive course,
onset in the LL, rare
pain and dysesthesia,
early ataxia, possible
face or trunk
involvement
Onset at early or late
age, slow
progression, marked
ataxia
More rapid
progression, less
severe involvement,
possible
asymmetrical
distribution
Most frequent
etiologies
Paraneoplastic and
toxic
Inherited, dysimmune,
and idiopathic
Inherited and idiopathic Idiopathic and
dysimmune
Specific paraclinical
abnormalities
Abnormal CSF and
MCV point to
paraneoplastic SNN
— Severe reduction of
SAP with at least one
SAP abolished in the
upper limbs
SAP less severely
altered
CSF, cerebrospinal fluid; LL, lower limb; MCV, motor conduction velocity; SAP, sensory action potential; SNN, sensory neuronopathy.
more severe disease marked by at least one abolished
SAP in the upper limbs (OR 27.1: 7.1–267.8 95% CI, p
< 0.01). Using the ROC curve (Fig. 3B), the presence
of at least three of these criteria identified patients
in group C with 93% sensitivity and 78% specificity.
On applying these criteria to those patients in the
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A B
Figure 3. Receiver operating characteristic curves for the sensitivity and specificity of the two sets of criteria distinguishing
pattern A from pattern B (A) and pattern C from pattern D (B) in the study population. The area under the curve is 0.906
(0.854–0.968 95% confidence interval [CI]) and 0.927 (0.871–0.983 95% CI), respectively.
Figure 4. Distribution of cases in the two populations after application of the different patterns of criteria elaborated by
logistic regression. DYS, dysimmune sensory neuronopathy (SNN); GEN, genetic SNN; ID, idiopathic SNN; INF, infectious
SNN; OTHER, other etiologies of SNN; PARA, paraneoplastic SNN; SP, study population; TOX, toxic SNN; CP, control/test
population.
study population not identified in the previous step as
conforming to pattern A (Fig. 4), pattern C identified
100% of cases of inherited SNN (3/3) and 47% of
cases of idiopathic SNN (8/17), while pattern D identi-
fied 53% of cases of idiopathic SNN (9/17) and 83%
of cases of dysimmune SNN (5/6).
Elaboration of a strategy for the etiological
diagnosis of SNN
Using the results obtained above, a strategy was
developed with the study population and checked
against the test population, with the aim of allocating
each patient to the correct etiological group. This
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Figure 5. Proposed strategy for the etiological diagnosis of sensory neuronopathies (SNNs). AB, antibodies; AC, anticoagulant;
CSF, cerebrospinal fluid; MG, monoclonal gammopathy; SAP, sensory action potential; SS, Sjo¨gren’s syndrome.
strategy was based on the different clinical patterns
identified above and on the facts that (1) some patients
did not follow these patterns, in particular patients with
seronegative or slowly evolving paraneoplastic SNN, in
whom the underlying tumor must not be missed and
(2) a dysimmune etiology sometimes appeared years
after the first referral. The number of patients identified
at each step is presented as a flow chart in Fig. S1
and the final strategy is summarized in Fig. 5. In all,
95.4% (84/88) of the patients in the study population
and 97% (58/60) patients in the test population were
correctly allocated to their final etiological diagnosis.
The four patients in the study population who were
misclassified (one with pattern C and three with pattern
A) developed an autoimmune context after an initial
negative workup, whereas the two patients in the
test population who were misclassified had either an
acute idiopathic SNN that did not follow pattern A or a
subacute SNN associated with Biermer’s disease that
was missed, as B12 levels were not initially included
in the laboratory investigations.
If we consider the group of 10 patients in the study
population for whom the time between onset and etio-
logical diagnosis was 1–10 years, the use of this strat-
egy would have led to the correct etiological diagnosis
in 5/5 cases of paraneoplastic SNN (4 with Hu anti-
bodies not initially tested and 1 seronegative patient)
and 3/5 cases of dysimmune SNN. Of the 22 patients
with an initial negative workup and a final diagnosis of
idiopathic SNN after a follow-up of up to 20 years, a
diagnosis of chronic idiopathic SNN would have been
predicted after the first referral in 59% (13 patients).
Discussion
Although different types of SNN share clinical
and electrophysiological features that allow them to
be distinguished from other sensory neuropathies
(Camdessanche´ et al., 2009), they show identifiable
differences related to the etiology. A better knowledge
of the clinical and electrophysiological patterns of SNN
may help to determine the best strategy for searching
for the underlying etiology (Graus et al., 2004). Such
a strategy has to take into account several difficulties.
First, some etiological groups are heterogeneous,
for example, idiopathic SNN can sometimes involve
immunity (Colli et al., 2008) and dysimmune SNN
can follow an acute, subacute, or progressive course,
implying different mechanisms. Second, in the case of
paraneoplastic or dysimmune SNN, the cause of the
neuropathy may only be revealed months or years later.
Third, for a given etiology, some patients deviate from
the expected pattern, as is the case in paraneoplastic
SNN, which sometimes follows a protracted and
indolent course (Graus et al., 1994). It is therefore
important to identify, as soon as possible, those
patients for whom a frequent check is recommended
and this implies that the developed strategy relies on
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clinical characteristics available at onset or early in the
evolution of the neuropathy.
MCA, which does not identify groups of patients
from an a priori point of view, but by whether their
clinical characteristics are similar or dissimilar, allowed
the characterization of four clinical patterns that are
clearly linked to underlying causes of the neuropathy.
Interestingly, multivariate logistic regression showed
that items observable early in the evolution could
identify these patterns with good sensitivity and
specificity. For example, 64% of patients with an acute
or subacute onset involving the upper limbs, with pain,
and an age over 60 (pattern A) had paraneoplastic
or toxic SNN and this pattern identified 91% of
patients with these etiologies. However, this pattern
also occurs with infectious SNN and sometimes with
idiopathic or dysimmune SNN. An abnormal CSF is
typically indicative of a paraneoplastic or infectious
origin. Conversely, 91% of patients with a progressive
and painless evolution (pattern B) had inherited,
dysimmune, or idiopathic SNN and this pattern
identified 100%, 60%, and 67% of cases with these
respective etiologies. Patterns C and D are subgroups
of pattern B. Pattern C characterizes patients with a
very slow progressive course, an early marked ataxia
without pain or dysesthesia, and a severe and diffuse
alteration of SAPs. Especially if the lower limbs are
affected first, this pattern typically indicates idiopathic
SNN in older patients, while, in younger patients, it
is suggestive of an inherited disorder. Conversely,
pattern D characterizes patients with a more rapid
course, mild ataxia, and sometimes asymmetric
symptoms, and 56% of patients with this pattern
have dysimmune, or occasionally paraneoplastic, SNN
(Graus et al., 1994), while, in 40.6%, no etiology is
found. Thus, as some cases of idiopathic SNN are
indistinguishable from dysimmune SNN, patients with
pattern D should be frequently investigated for the
appearance of a dysimmune context, which developed
in 31% of cases in the study population. At present,
it is not known whether this dysimmune context,
mainly Sjo¨gren’s syndrome, is the true cause of
the neuropathy or whether this results from the
association of two autoimmune diseases (Dyck, 2005).
Conversely, the probability that patients with pattern C
have an autoimmune disease does not exceed 12%,
suggesting that close checking may not be warranted.
The complexity of SNN points to the need for a
diagnostic strategy that takes into account the different
issues discussed above. The strategy proposed here
can be summarized as follows (Fig. 5): in a patient with
possible SNN, it is necessary to take into account age
at onset, family history, toxic habits, including alcohol
consumption, and treatments, such as chemotherapy
and chronic B6 intake. Whatever the evolution, the
initial laboratory investigations should systematically
include a search for anti-nuclear (ANA), SSA, or SSB
antibodies and B12 vitamin deficiency. Screening
for onconeural antibodies is also necessary to allow
the identification of the majority of paraneoplastic
SNN cases, including those with an atypical clinical
presentation (e.g., with an indolent or protracted
course). If one of these investigations is positive,
an etiological diagnosis can be made. In our series,
40% of the study patients were diagnosed at this
stage. If the workup is negative, the pattern of the
neuropathy is determinant. Patients with pattern A
should be investigated for toxic causes. If the CSF is
abnormal, a check for an infectious disease, including
HIV, is recommended and, if this is negative, the 18
fluorodesoxyglucose-positron emission tomography
(FDG-PET), scanner must be used to exclude a
seronegative paraneoplastic disorder (Antoine et al.,
2000). In those patients who do not conform to pattern
A, if the evolution is progressive and the patient fits
to pattern D, a young age or family history points
to an inherited disease, while older age probably
suggests an idiopathic form. With pattern C, a frequent
checkup for autoimmunity is warranted, especially
if the patient is a young female. The presence of
monoclonal gammopathy may point to a dysimmune
disorder and monoclonal IgM should be tested for anti-
disialosyl ganglioside reactivity. Finally, one interesting
finding is that some patients with apparently idiopathic
SNN show a pattern identical to that of dysimmune
SSN, which may suggest that these neuropathies also
involve autoimmune mechanisms.
Appendix
The French CIDP Study Group: Other members
of the French CIDP group who provided cases
for the study are, in alphabetical order: Franc¸oise
Bouhour, CHU de Lyon, France; Pierre Clavelou,
CHU de Clermont-Ferrand, France; Andoni Echaniz-
Laguna, CHU de Strasbourg, France; He´le`ne Gervais-
Bernard, CHU de Lyon, France; Joerg Kleeberg,
CHUV Lausanne, Switzerland; Emeline Lagrange,
CHU de Grenoble, France; Jean-Pascal Lefaucheur,
CHU de Cre´teil, France; Jean-Marc Le´ger, Hoˆpital
de la Salpetrie`re, Paris, France; Stephane Mathis,
CHU de Poitiers, France; Guillaume Nicolas, CHU
Angers, France; Franc¸ois Ochsner, La Chaux-de-Fond,
Switzerland; Yann Pe´re´on, CHU de Nantes, France;
Philippe Petiot, CHU Lyon, France; Pierre Soichot,
CHU de Dijon, France; Guillaume Taı¨eb, CHU de
Nimes, France; Jean-Michel Vallat, CHU de Limoges,
France; Christophe Vial, CHU Lyon, France; Karine
Viala, Hoˆpital de la Salpetrie`re, Paris, France.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Flow chart showing the results of the diagnosis
strategy for the etiology of sensory neuronopathy (SNN).
Figures associated with the arrows indicate the number of
patients selected at each step of the procedure. Those of
the study population are in normal font, while bold and italic
font indicates the control population. Black arrows indicate
patients with a final diagnosis of dysimmune (DYS) SNN obtained
with follow-up in the study population. A-SA, acute–subacute;
AB, antibodies; CSF, cerebrospinal fluid; MG, monoclonal
gammopathy; P, progressive; SAP, sensory action potential;
SS, Sjo¨gren syndrome.
Please note: Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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